

Lecithin

1 Nonproprietary Names

USPNF: Lecithin
See also Section 4.

2 Synonyms

E322; egg lecithin; LSC; mixed soybean phosphatides; ovo-lecithin; Phosal 53 MCT; Phospholipon 100 H; soybean lecithin; soybean phospholipids; Sternphil; Sternpur; Sternwet; vegetable lecithin; Yollkin IP 4913.

3 Chemical Name and CAS Registry Number

Lecithin [8002-43-5]

The chemical nomenclature and CAS Registry numbering of lecithin is complex. The commercially available lecithin, used in cosmetics, pharmaceuticals, and food products, is a complex mixture of phospholipids and other materials. However, it may be referred to in some literature sources as 1,2-diacyl-*sn*-glycero-3-phosphocholine (trivial chemical name, phosphatidylcholine). This material is the principal constituent of egg lecithin and has the same CAS Registry Number. The name lecithin and the CAS Registry Number above are thus used to refer to both lecithin and phosphatidylcholine in some literature sources.

Another principal source of lecithin is from an extract of soybeans (CAS [8030-76-0]). Egg yolk lecithin (CAS [93685-90-6]) is also listed in *Chemical Abstracts*.


See also Section 4.

4 Empirical Formula Molecular Weight

The USPNF 20 describes lecithin as a complex mixture of acetone-insoluble phosphatides that consists chiefly of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and phosphatidylinositol, combined with various amounts of other substances such as triglycerides, fatty acids, and carbohydrates as separated from a crude vegetable oil source.

The composition of lecithin (and hence also its physical properties) varies enormously depending upon the source of the lecithin and the degree of purification. Egg lecithin, for example, contains 69% phosphatidylcholine and 24% phosphatidylethanolamine, while soybean lecithin contains 21% phosphatidylcholine, 22% phosphatidylethanolamine, and 19% phosphatidylinositol, along with other components.⁽¹⁾

5 Structural Formula



α -Phosphatidylcholine

R¹ and R² are fatty acids, which may be different or identical.

Lecithin is a complex mixture of materials; see Section 4. The structure above shows phosphatidylcholine, the principal component of egg lecithin, in its α -form. In the β -form, the phosphorus-containing group and the R² group exchange positions.

6 Functional Category

Emollient; emulsifying agent; solubilizing agent.

7 Applications in Pharmaceutical Formulation or Technology

Lecithins are used in a wide variety of pharmaceutical applications; see Table I. They are also used in cosmetics⁽²⁾ and food products.

Lecithins are mainly used in pharmaceutical products as dispersing, emulsifying, and stabilizing agents and are included in intramuscular and intravenous injections, parenteral nutrition formulations, and topical products such as creams and ointments.

Lecithins are also used in suppository bases,⁽³⁾ to reduce the brittleness of suppositories, and have been investigated for their absorption-enhancing properties in an intranasal insulin formulation.⁽⁴⁾ Lecithins are also commonly used as a component of enteral and parenteral nutrition formulations.

There is evidence that phosphatidylcholine (a major component of lecithin) is important as a nutritional supplement to fetal and infant development. Furthermore, choline is a required component of FDA-approved infant formulas.⁽⁵⁾ Other studies have indicated that lecithin can protect against alcohol cirrhosis of the liver, lower serum cholesterol levels, and improve mental and physical performance.⁽⁶⁾

Liposomes in which lecithin is included as a component of the bilayer have been used to encapsulate drug substances; their potential as novel delivery systems has been investigated.⁽⁷⁾ This application generally requires purified lecithins combined in specific proportions.

Therapeutically, lecithin and derivatives have been used as a pulmonary surfactant in the treatment of neonatal respiratory distress syndrome.

Table I: Uses of lecithin.

Use	Concentration (%)
Aerosol inhalation	0.1
IM injection	0.3–2.3
Oral suspensions	0.25–10.0

8 Description

Lecithins vary greatly in their physical form, from viscous semiliquids to powders, depending upon the free fatty acid content. They may also vary in color from brown to light yellow, depending upon whether they are bleached or unbleached or on the degree of purity. When they are exposed

to air, rapid oxidation occurs, also resulting in a dark yellow or brown color.

Lecithins have practically no odor. Those derived from vegetable sources have a bland or nutlike taste, similar to that of soybean oil.

9 Pharmacopeial Specifications

See Table II.

Table II: Pharmacopeial specifications for lecithin.

Test	USPNF 20
Water	≤ 1.5%
Lead	≤ 0.001%
Heavy metals	≤ 20 µg/g
Acid value	+
Hexane-insoluble matter	≤ 0.3%
Acetone-insoluble matter	≥ 50.0%
Organic volatile impurities	+

10 Typical Properties

Density:

0.97 g/cm³ for liquid lecithin

0.5 g/cm³ for powdered lecithin

Iodine number:

95–100 for liquid lecithin

82–88 for powdered lecithin

Isoelectric point: ≈ 3.5

Saponification value: 196

Solubility: lecithins are soluble in aliphatic and aromatic hydrocarbons, halogenated hydrocarbons, mineral oil, and fatty acids. They are practically insoluble in cold vegetable and animal oils, polar solvents, and water. When mixed with water, however, lecithins hydrate to form emulsions.

11 Stability and Storage Conditions

Lecithins decompose at extreme pH. They are also hygroscopic and subject to microbial degradation. When heated, lecithins oxidize, darken, and decompose. Temperatures of 160–180°C will cause degradation within 24 hours.

Fluid or waxy lecithin grades should be stored at room temperature or above; temperatures below 10°C may cause separation.

All lecithin grades should be stored in well-closed containers protected from light and oxidation. Purified solid lecithins should be stored in tightly closed containers at subfreezing temperatures.

12 Incompatibilities

Incompatible with esterases owing to hydrolysis.

13 Method of Manufacture

Lecithins are essential components of cell membranes and, in principle, may be obtained from a wide variety of living matter. In practice, however, lecithins are usually obtained from vegetable products such as soybean, peanut, cottonseed, sunflower, rapeseed, corn, or groundnut oils. Soybean lecithin is the most commercially important vegetable lecithin. Lecithin

obtained from eggs is also commercially important and was the first lecithin to be discovered.

Vegetable lecithins are obtained as a by-product in the vegetable oil refining process. Polar lipids are extracted with hexane and, after removal of the solvent, a crude vegetable oil is obtained. Lecithin is then removed from the crude oil by water extraction. Following drying, the lecithin may be further purified.⁽¹⁾

With egg lecithin, a different manufacturing process must be used since the lecithin in egg yolks is more tightly bound to proteins than in vegetable sources. Egg lecithin is thus obtained by solvent extraction from liquid egg yolks using acetone or from freeze-dried egg yolks using ethanol.⁽¹⁾

Synthetic lecithins may also be produced.

14 Safety

Lecithin is a component of cell membranes and is therefore consumed as a normal part of the diet. Although excessive consumption may be harmful, it is highly biocompatible and oral doses of up to 80 g daily have been used therapeutically in the treatment of tardive dyskinesia.⁽⁸⁾ When used in topical formulations, lecithin is generally regarded as a nonirritant and nonsensitizing material.⁽²⁾ The Cosmetic Ingredients Review Expert Panel (CIR) has reviewed lecithin and issued a tentative report revising the safe concentration of the material from 1.95% to 15.0% in rinse-off and leave-in products. They note, however, that there are insufficient data to rule on products that are likely to be inhaled.⁽⁹⁾

15 Handling Precautions

Observe normal precautions appropriate to the circumstances and quantity of material handled. Lecithins may be irritant to the eyes; eye protection and gloves are recommended.

16 Regulatory Status

GRAS listed. Accepted as a food additive in Europe. Included in the FDA Inactive Ingredients Guide (inhalations; IM and IV injections; oral capsules, suspensions and tablets; rectal, topical, and vaginal preparations). Included in nonparenteral and parenteral medicines licensed in the UK.

17 Related Substances

—

18 Comments

Lecithins contain a variety of unspecified materials; care should therefore be exercised in the use of unpurified lecithin in injectable or topical dosage forms, as interactions with the active substance or other excipients may occur. Unpurified lecithins may also have a greater potential for irritancy in formulations.

Supplier's literature should be consulted for information on the different grades of lecithin available and their applications in formulations.

The EINECS number for lecithin is 232-307-2.

19 Specific References

- Schneider M. Achieving purer lecithin. *Drug Cosmet Ind* 1992; 150(2): 54, 56, 62, 64, 66, 101–103.

- 2 Anonymous. Lecithin: its composition, properties and use in cosmetic formulations. *Cosmet Perfum* 1974; 89(7): 31–35.
- 3 Novak E, Osborne DW, Matheson LE, *et al.* Evaluation of cefmetazole rectal suppository formulation. *Drug Dev Ind Pharm* 1991; 17(3): 373–389.
- 4 Anonymous. Intranasal insulin formulation reported to be promising. *Pharm J* 1991; 247: 17.
- 5 US Congress. Infant Formula Act of 1980. Public Law 96-359, 1980.
- 6 Canty D, Zeisel S, Jolitz A. *Lecithin and Choline Research Update on Health and Nutrition*. Fort Wayne, IN: Central Soya Company, Inc., 1996.
- 7 Grit M, Zuidam NJ, Underberg WJM, Crommelin DJA. Hydrolysis of partially saturated egg phosphatidylcholine in aqueous liposome dispersions and the effect of cholesterol incorporation on hydrolysis kinetics. *J Pharm Pharmacol* 1993; 45: 490–495.
- 8 Growdon JH, Gelenberg AJ, Doller J, *et al.* Lecithin can suppress tardive dyskinesia [letter]. *N Engl J Med* 1978; 298: 1029–1030.
- 9 Anonymous. 'The Rose Sheet' *FDC Reports* 1997; 18(39): 8.

20 General References

- Arias C, Rueda C. Comparative study of lipid systems from various sources by rotational viscometry and potentiometry. *Drug Dev Ind Pharm* 1992; 18: 1773–1786.
- Hanin I, Pepeu G, eds. *Phospholipids: Biochemical, Pharmaceutical and Analytical Considerations*. New York: Plenum Press, 1990.

21 Author

K Fowler.

22 Date of Revision

14 October 2002.